Plasma Derived Therapies Market Size is valued at USD 22.36 Bn in 2025 and is predicted to reach USD 46.62 Bn by the year 2035 at 8.2% CAGR during the forecast period for 2026 to 2035.
Plasma Derived Therapies Market Size, Share & Trends Analysis Report by Product Type (Immunoglobulin, Coagulation Factors, Albumin), Application Type (Haemophilia, Primary Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura), Region And Segment Forecasts, 2026 to 2035
Immune deficiencies, bleeding problems, and genetic diseases are only some conditions that must be treated using plasma-derived therapies. Plasma fractionation, which involves separating and purifying the plasma to remove particular proteins or antibodies, is the method used to produce plasma-derived medicines. High frequency of chronic blood illnesses, improvements in plasma collection & fractionation technology, and increased need for safe, efficient, and minimally invasive treatment techniques are projected to boost the market for plasma-derived therapeutics.
The global ageing population, as well as the increased frequency of chronic diseases, are significant factors driving this market. Immune deficiencies, haemophilia, and liver illnesses are among the many diseases that can be treated with plasma-derived therapies such as immunoglobulins, clotting factors, and albumin. The expanding patient population and the need for efficient therapeutic choices drive the need for plasma-derived therapeutics.
Improvements in plasma fractionation methods and technology facilitate market expansion. Advances in plasma collection, processing, and purification techniques have resulted from ongoing research and development in the biotechnology and healthcare fields. These developments raise the effectiveness and security of plasma-derived medicines, further promoting their market adoption.
The rising incidence of chronic illnesses and rare disorders among people has emerged as a crucial growth element that has assisted the market in achieving a considerable position. In order to offer cutting-edge healthcare facilities that will significantly benefit society, both the government and private organisations have launched numerous measures. People have been encouraged to use these advanced treatment options in order to get the best results, thanks to multiple government efforts that provide reimbursement options through insurance companies.
The Plasma Derived Therapies market is segmented on the basis of product type and application type. The market is segmented as Immunoglobulin, Coagulation factors, Albumin, and Others based on product type. The market is segmented by application type into Haemophilia, Primary Immunodeficiency Disease, Idiopathic Thrombocytopenic Purpura, and others.
The immunoglobulin segment is anticipated to rule the market during the projected period. Numerous immunological deficiencies and autoimmune diseases are commonly treated using immunoglobulins. The demand for immunoglobulin therapy is driven by the rising prevalence of these diseases as well as rising awareness and diagnosis. Improvements in immunoglobulin production and purification due to advances in plasma fractionation techniques have raised the bar for both quality and safety. Additionally, improved access to immunoglobulin therapy has increased access to healthcare facilities, particularly in emerging economies, further strengthening their market domination.
The haemophilia segment is projected to grow at a rapid rate in the global Plasma Derived Therapies market as it is a persistent bleeding disorder that needs to be regularly treated with plasma-derived clotting factors. The rising prevalence of haemophilia and improvements in available treatments drives the demand for plasma-derived therapeutics in this market. Second, the care of haemophilia has been greatly improved, improving patient outcomes, with the availability of recombinant clotting factors and extended half-life medicines. Additionally, the dominance of the haemophilia segment in the market for plasma-derived therapeutics is attributed to the increasing awareness and diagnosis of haemophilia, as well as supportive government initiatives and the development of the healthcare infrastructure.
The projection period is expected to see North America dominate the global market, which was valued at USD 16.10 billion in 2022. Several variables are responsible for this region's largest market share. Major corporations that create and sell technologically cutting-edge plasma-derived therapies and goods are some of the variables that favourably influence the region's development.
Additionally, the U.S. having the greatest concentration of plasma fractionation facilities greatly impacts the market's expansion. The second-largest market share belonged to Europe, on the other hand. This is because immunodeficiency and bleeding disorders are becoming more common in the area, and increased investments in these systems are accelerating market growth in the area.
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 22.36 Bn |
| Revenue Forecast In 2035 | USD 46.62 Bn |
| Growth Rate CAGR | CAGR of 8.2% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million, and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2024 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, Kedrion, and Pfizer Inc. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Plasma Derived Therapies Market By Product Type-
Plasma Derived Therapies Market By Application Type-
Plasma Derived Therapies Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.